Clinical trial · Interventional
506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Compound 506U78 (NSC 686673) in Patients With Relapsed or Refractory T-Cell ALL or T-Cell Lymphoblastic Lymphoma
NCT00003837CI-TRIAL-00010888completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Clinical trial to study the effectiveness of 506U78 in treating patients who have relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nelarabine | Drug | Nelarabine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Provide an investigational agent to physicians for patients who are not candidates for entry onto ongoing research clinical trials of higher priority
Secondary outcomes (2)
- measure
- Toxicity
- measure
- Antitumor efficacy as defined by the rate of complete hematologic responses
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma * Tumor cells should exhibit phenotypic characteristics of these diseases * No CNS involvement requiring intrathecal or craniospinal radiotherapy * Must not be eligible for Intergroup, Cooperative Group, or local research studies of higher priority PATIENT CHARACTERISTICS: Age: * 16 and over Performance status: * ECOG 0-3 OR * Karnofsky 40-100% Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Bilirubin no greater than 2.0 mg/dL Renal: * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance at least 50 mL/min Other: * No neuropathy grade 2 or higher * No history of significant neurological toxicity (grade 2 or greater) associated with prior chemotherapy or radiotherapy * No active seizure disorder * No active infection * No other active concurrent malignancy except curatively treated basal cell carcinoma or carcinoma in situ of the cervix * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Prior bone marrow transplantation allowed * No concurrent allogeneic bone marrow transplantation Chemotherapy: * At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered * No prior 506U78 Endocrine therapy: * No concurrent systemic steroid therapy Radiotherapy: * See Disease Characteristics * Prior radiotherapy allowed Surgery: * Not specified Other: * No other concurrent investigational therapy * No concurrent treatment for seizures
References
Publications (0)
Data not yet available
No reference posted for this study.